An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability
Marit J. van Gils(Amsterdam University Medical Centers), Rogier W. Sanders(Scripps Research Institute), Hanneke Schuitemaker(Johnson & Johnson (Israel)), Steven W. de Taeye(Sanquin), Inez Johanna(Utrecht University), John P. Moore(Cornell University), Jesper Pallesen(Scripps Research Institute), Anila Yasmeen(Cornell University), Gabriel Ozorowski(Scripps Research Institute), Devin Sok(Scripps Research Institute), Max Crispin(University of Southampton), Per Johan Klasse(Cornell University), Christopher A. Cottrell(Scripps Research Institute), Karen L. Saye-Francisco(Scripps Research Institute), Dennis R. Burton(Scripps Research Institute), Natalia de Val(National Institutes of Health), Garnett Kelsoe(Duke University), Anna Schorcht(Amsterdam UMC Location University of Amsterdam), Andrew B. Ward(Scripps Research Institute), Tom L.G.M. van den Kerkhof(Amsterdam UMC Location University of Amsterdam), Elise Landais(Scripps Research Institute), Stephanie B. H. Gumbs(University Medical Center Utrecht), Laura K. Pritchard(Virginia Commonwealth University), Xiaoyan Nie(Duke University), Matthias Pauthner(Scripps Research Institute), Chi-Hui Liang(Scripps Research Institute), Ian A. Wilson(Raigmore Hospital)
Cited by 164
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Site-specific glycan analysis of the SARS-CoV-2 spike
|Science|2020|1.7k
Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples
|Nature Protocols|2017|1.3k
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
|Proceedings of the National Academy of Sciences|2017|1.2k